{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:07:36Z","timestamp":1789556856621,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113603","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:38:48Z","timestamp":1707136728000},"page":"113603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effectiveness and safety of COVID-19 vaccination in people with blood cancer"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-5241","authenticated-orcid":false,"given":"Emma","family":"Copland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8416-2159","authenticated-orcid":false,"given":"Jennifer","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5954-1045","authenticated-orcid":false,"given":"Martina","family":"Patone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9849-4966","authenticated-orcid":false,"given":"Daniel","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-3306","authenticated-orcid":false,"given":"Carol","family":"Coupland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-7283","authenticated-orcid":false,"given":"Julia","family":"Hippisley-Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.113603_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","article-title":"Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer","volume":"8","author":"Chavez-MacGregor","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.113603_bib2","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2024.113603_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2021.10.014","article-title":"Immunogenicity and risk of severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis","volume":"160","author":"Becerril-Gaitan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.113603_bib4","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)","volume":"75","author":"Haidar","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ejca.2024.113603_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.113603_bib6","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1093\/oncolo\/oyac032","article-title":"Impact of therapy in patients with hematologic malignancies on seroconversion rates after SARS-CoV-2 Vaccination","volume":"27","author":"Guven","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejca.2024.113603_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-021-01219-7","article-title":"Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia","volume":"15","author":"Parry","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.113603_bib8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/eji.202149771","article-title":"SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination","volume":"52","author":"Jarisch","year":"2022","journal-title":"Eur J Immunol"},{"issue":"17","key":"10.1016\/j.ejca.2024.113603_bib9","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.3390\/cancers13174480","article-title":"Poor neutralizing antibody responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejca.2024.113603_bib10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","article-title":"Antibody response in immunocompromised patients with hematologic cancers who received a 3-Dose mRNA-1273 vaccination schedule for COVID-19","volume":"8","author":"Haggenburg","year":"2022","journal-title":"JAMA Oncol"},{"issue":"704","key":"10.1016\/j.ejca.2024.113603_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg9452","article-title":"Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states","volume":"15","author":"M\u00fcller","year":"2023","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ejca.2024.113603_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review","volume":"12","author":"Piechotta","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.ejca.2024.113603_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13835","article-title":"COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients","volume":"24","author":"DeVoe","year":"2022","journal-title":"Transpl Infect Dis"},{"issue":"18","key":"10.1016\/j.ejca.2024.113603_bib14","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/cncr.34354","article-title":"Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies","volume":"128","author":"Ollila","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2024.113603_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-021-00487-z","article-title":"COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials","volume":"18","author":"Desai","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113603_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100984","article-title":"SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies","volume":"56","author":"Ni","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.ejca.2024.113603_bib17","unstructured":"UK Health Security Agency. JCVI advises an autumn COVID-19 vaccine booster. 25 January 2023. 2023 \u3008https:\/\/www.gov.uk\/government\/news\/jcvi-advises-an-autumn-covid-19-vaccine-booster\u3009."},{"key":"10.1016\/j.ejca.2024.113603_bib18","doi-asserted-by":"crossref","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2024.113603_bib19","doi-asserted-by":"crossref","unstructured":"Hirst J., Mi E., Copland E., Patone M., Coupland C., Hippisley-Cox J. Uptake of COVID-19 vaccination in people with blood cancer: population-level cohort study of 12 million patients in England. European Journal of Cancer 2023.","DOI":"10.2139\/ssrn.4557702"},{"key":"10.1016\/j.ejca.2024.113603_bib20","unstructured":"Brighton Collaboration. SO2-D2.1.2 Priority List of COVID-19 Adverse events of special interest: Quarterly update December 2020. 2021. \u3008https:\/\/covid-19pharmacovigilance.paho.org\/img\/recursos\/6070d276689bb7c080e623190.pdf\u3009."},{"issue":"8","key":"10.1016\/j.ejca.2024.113603_bib21","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.vaccine.2021.11.061","article-title":"COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: a national prospective cohort study in Wales","volume":"40","author":"Bedston","year":"2022","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ejca.2024.113603_bib22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2024.113603_bib23","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2468-2667(23)00079-8","article-title":"Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform","volume":"8","author":"Nab","year":"2023","journal-title":"Lancet Public Health"},{"issue":"10","key":"10.1016\/j.ejca.2024.113603_bib24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.annonc.2021.07.002","article-title":"Severe COVID-19 in patients with hematological cancers presenting with viremia","volume":"32","author":"Michot","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113603_bib25","first-page":"81","article-title":"Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma","volume":"4","author":"Keppler-Hafkemeyer","year":"2023","journal-title":"Nat"},{"issue":"6","key":"10.1016\/j.ejca.2024.113603_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjh.18149","article-title":"Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination","volume":"197","author":"Riise","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ejca.2024.113603_bib27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Dul\u00e9ry","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113603_bib28","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies","volume":"13","author":"Re","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ejca.2024.113603_bib29","article-title":"Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer","volume":"3","author":"Fendler","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ejca.2024.113603_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.038","article-title":"COVID-19: third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study","volume":"175","author":"Lee","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113603_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejca.2022.01.035","article-title":"Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients","volume":"165","author":"Heudel","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113603_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102981","article-title":"Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases","volume":"135","author":"Mrak","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ejca.2024.113603_bib33","doi-asserted-by":"crossref","first-page":"n1931","DOI":"10.1136\/bmj.n1931","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejca.2024.113603_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.17645","article-title":"Exacerbation of immune thrombocytopenia following COVID-19 vaccination","volume":"195","author":"Kuter","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2024.113603_bib35","unstructured":"Department of Health and Social Care. Defining the highest risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs (updated March 2023), 2023."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:07Z","timestamp":1760733787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"alternative-id":["S0959804924000790"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113603","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of COVID-19 vaccination in people with blood cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113603"}}